Nature Communications (Nov 2021)
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
- Matthew T. Campbell,
- Surena F. Matin,
- Alda L. Tam,
- Rahul A. Sheth,
- Kamran Ahrar,
- Rebecca S. Tidwell,
- Priya Rao,
- Jose A. Karam,
- Christopher G. Wood,
- Nizar M. Tannir,
- Eric Jonasch,
- Jianjun Gao,
- Amado J. Zurita,
- Amishi Y. Shah,
- Sonali Jindal,
- Fei Duan,
- Sreyashi Basu,
- Hong Chen,
- Alexsandra B. Espejo,
- James P. Allison,
- Shalini S. Yadav,
- Padmanee Sharma
Affiliations
- Matthew T. Campbell
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Surena F. Matin
- Department of Urology, The University of Texas MD Anderson Cancer Center
- Alda L. Tam
- Department of Interventional Radiology, The University of Texas of MD Anderson Cancer Center
- Rahul A. Sheth
- Department of Interventional Radiology, The University of Texas of MD Anderson Cancer Center
- Kamran Ahrar
- Department of Interventional Radiology, The University of Texas of MD Anderson Cancer Center
- Rebecca S. Tidwell
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Priya Rao
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Jose A. Karam
- Department of Urology, The University of Texas MD Anderson Cancer Center
- Christopher G. Wood
- Department of Urology, The University of Texas MD Anderson Cancer Center
- Nizar M. Tannir
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Eric Jonasch
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Jianjun Gao
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Amado J. Zurita
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Amishi Y. Shah
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- Sonali Jindal
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Fei Duan
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Sreyashi Basu
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Hong Chen
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Alexsandra B. Espejo
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- James P. Allison
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Shalini S. Yadav
- The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center
- Padmanee Sharma
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
- DOI
- https://doi.org/10.1038/s41467-021-26415-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Anti-CTLA4 therapy has not been comprehensively explored for the treatment of metastatic renal cell carcinoma (mRCC). Here, in a pilot study of anti-CTLA4 therapy with or without cryoablation in mRCC, the authors report that the combination is feasible and enhances immune infiltration in patients with metastatic clear cell histology.
